focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksGlaxosmithkline Share News (GSK)

Share Price Information for Glaxosmithkline (GSK)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 1,793.50
Bid: 1,793.00
Ask: 1,794.00
Change: -19.00 (-1.05%)
Spread: 1.00 (0.056%)
Open: 1,792.50
High: 1,802.00
Low: 1,792.00
Prev. Close: 1,812.50
GSK Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON MARKET CLOSE: Stocks Rebound; RSA Surges On Zurich's Interest

Tue, 28th Jul 2015 16:00

LONDON (Alliance News) - UK shares ended higher Tuesday, together with other major European equities markets, while the pound strengthened against the dollar following a reassuring reading of second quarter UK GDP.

On the corporate front, RSA Insurance shares surged after Switzerland's Zurich Insurance confirmed it is evaluating a potential offer for the FTSE 100 company. At the other end of the table, Royal Mail led the blue-chip losers after UK regulator Ofcom said its provisional view is that the postal company breached competition law in its wholesale pricing to competitors.

The FTSE 100 closed up 0.8% at 6,555.28, taking back about half of Monday's losses. The FTSE 250 ended up 0.7% at 17,387.89, and the AIM All-Share index finished up 0.2% at 749.16.

European major indices also improved, with the CAC 40 in Paris adding 1.0% and the DAX 30 in Frankfurt climbing 1.1%.

The pound rose sharply against other major currencies following UK GDP data, which came in as expected, coming off session lows of USD1.5526 against the dollar.

The UK economy expanded at a faster pace in the second quarter, largely driven by an improvement in services output, a preliminary estimate from the Office for National Statistics showed. Gross domestic product grew 0.7% quarter-on-quarter, in line with forecasts, following a 0.4% rise in the first quarter.

Services expanded 0.7% and production increased 1%. Construction growth came in flat, and agriculture contracted 0.7%. UK GDP was 2.6% higher in the second quarter compared with the same quarter a year ago. The annual growth figure also matched expectations.

After the UK GDP release, better-than-expected readings from the US Markit services and composite purchasing managers' indices weren't enough to pull the dollar back up against the pound. Sterling remained higher against the greenback after subsequent disappointing US consumer confidence data.

Confidence among US consumers saw a substantial deterioration in the month of July, according to a report released by the US Conference Board. The US Conference Board said its consumer confidence index tumbled to 90.9 in July from a downwardly revised 99.8 in June. Economists had expected the index to show a much more modest decrease to a reading of 99.6 from the 101.4 originally reported for the previous month.

Markit services PMI came in at 55.2 for the US, slightly above economist expectations for a 55.0 reading, and also above the 54.8 reading seen in June. The composite index also read 55.2, ahead of the 54.6 level a month ago.

At the European stock markets close, the pound was trading at USD1.5597, slightly up from USD1.5577 at Monday's equities close in London.

The US Federal Open Market Committee begins on Tuesday its two-day meeting ahead of its interest rate announcement on Wednesday at 1900 BST.

The Fed is widely expected to leave US interest rates unchanged at the meeting. However, investors will pay attention to the accompanying monetary policy statement, after a recent hawkish speech and Congressional testimony by Fed Chair Janet Yellen intensified expectations that the bank would hike rates later this year.

Many analysts still expect the Fed to raise US interest rates at its next meeting in September and will be closely scrutinizing the statement for any hints about the timing of the first US rate hike in nine years.

At the European equity markets close, Wall Street was higher, with the Dow 30 up 0.6%, the S&P 500 up 0.7%, and the Nasdaq Composite up 0.4%. In a busy day in the US earnings calendar, online social networking service Twitter, biotechnology company Gilead Sciences, and online business review site Yelp are yet expected to release updates after the New York market close.

On the London Stock Exchange, RSA Insurance was the best performer in the FTSE 100, up 16%, after Zurich Insurance said it is evaluating a potential bid for RSA. After the Swiss insurer's announcement early Tuesday, RSA said it has not held talks or received any offer from its European peer. Zurich had said its announcement does not represent a firm offer to buy RSA and said there is no assurance that any offer will be made.

Following Zurich's statement, Shore Capital upgraded its rating on RSA Insurance Group to Buy from Hold. Shore analyst Eamonn Flanagan said that despite the group's recent problems there are some "terrific assets" in RSA which would be attractive to potential buyers. In addition, following the rights issue and disposals, the analyst said the group is pretty well capitalised.

Hikma Pharmaceuticals ended up 12% at 2,327.80 pence, after it said it has agreed a USD2.65 billion deal to acquire Roxane Laboratories and Boehringer Ingelheim Roxane from Boehringer Ingelheim, the German pharmaceutical company. Under the terms of the deal, Hikma will issue 40 million shares to Boehringer at 2,350 pence per share, along with a USD1.18 billion cash payment. This will give Boehringer an around 16.71% interest in the company.

Hikma said that Boehringer's investment in Hikma's shares at a premium reflected Boehringer's confidence in the value creation potential for them as long-term shareholders.

GKN closed up 6.5%. The engineer said it has agreed a EUR706 million deal to acquire Netherlands-based Fokker Technologies Group, while reporting a fall in pretax profit for the first half of 2015 thanks to weakness in some of its key end markets. GKN said it will pay EUR706 million to acquire Fokker Technologies, a Dutch maker of aerostructures, electrical wiring systems, landing gear and associated services. GKN said the deal will strengthen its position in the aerospace market and will expand its presence in the Chinese, Turkish, Indian and Mexican markets.

News of the acquisition eclipsed any concerns about GKN's first-half results. GKN's pretax profit for the six months to the end of June was down to GBP212 million from GBP224 million a year earlier, despite an increase in sales for the group to GBP3.62 billion from GBP3.57 billion.

Meanwhile, Royal Mail ended down 3.4% after UK media and communications regulator Ofcom said it has issued a statement of objections to the postal service operator, with a provisional view that the company breached competition law by discriminating in its wholesale pricing against postal operators that competed with it on delivery.

Ofcom said its provisional findings, part of the investigation launched following a complaint by Whistl, a former competitor of Royal Mail, are that Royal Mail's changes to prices, terms and conditions for the provision of access services included "unlawful price discrimination".

In response, Royal Mail said it was "disappointed" by the regulator's announcement and added it takes its compliance obligations "very seriously".

In the FTSE 250, Melrose Industries closed up 9.7% after it said it sold its Elster business to US industrial conglomerate Honeywell International for GBP3.3 billion in cash. It said that in addition to the cash consideration, Honeywell will assume the majority of the pension schemes on Melrose's books.

Melrose is planning to use the consideration for the Elster businesses to return more than GBP2 billion to its shareholders and for general corporate purposes, including paying down its debt obligations.

In a very busy corporate calendar Wednesday, among others, Sky releases full-year results and Barclays, Capita, Taylor Wimpey, St James's Place and British American Tobacco publish half-year results. Antofagasta issues a second-quarter production report, while Compass Group and Brewin Dolphin release interim management statements. GlaxoSmithKline releases its second-quarter results at 1200 BST.

In the economic calendar, the German Gfk consumer confidence survey is due at 0700 BST, while UK consumer credit and mortgage approvals data are due at 0930 BST. In the US, pending home sales are due at 1500 BST, while EIA Crude Oil stocks are at 1530 BST.

By Daniel Ruiz; danielruiz@alliancenews.com

Copyright 2015 Alliance News Limited. All Rights Reserved.

More News
1 Feb 2024 09:03

LONDON BROKER RATINGS: Barclays cuts Next; JPMorgan raises easyJet

(Alliance News) - The following London-listed shares received analyst recommendations Thursday morning:

Read more
1 Feb 2024 07:42

LONDON BRIEFING: Shell profit falls; announces USD3.5 billion buyback

(Alliance News) - Stocks in London are set to follow New York into the red, after the US Federal Reserve quashed hopes of a March cut to interest rates and ahead of the Bank of England interest rate decision.

Read more
31 Jan 2024 17:05

LONDON MARKET CLOSE: Stocks mixed hours before expected US Fed hold

(Alliance News) - Stock prices in London closed mixed on Wednesday in a trade-thinned day ahead of the US Federal Reserve interest rate decision this evening.

Read more
31 Jan 2024 15:49

London close: Stocks mixed ahead of US Fed, BoE decisions

(Sharecast News) - London's financial markets finished with mixed performance on Wednesday, with investors closing their wallets ahead of rate announcements from both the US Federal Reserve and the Bank of England.

Read more
31 Jan 2024 12:05

LONDON MARKET MIDDAY: FTSE 100 flat ahead of Federal Reserve decision

(Alliance News) - The FTSE 100 in London was flat heading into Wednesday afternoon, as the US Federal Reserve's latest interest rate decision edges closer, keeping equity market enthusiasm to a minimum.

Read more
31 Jan 2024 09:13

TOP NEWS: GSK profit up on Arexvy boost in 2023 but total payout down

(Alliance News) - GSK PLC reported an increase in profit and revenue for 2023 as revenue for HIV medicine had stable growth, amid optimism in the company's outlook.

Read more
31 Jan 2024 08:55

LONDON MARKET OPEN: Stocks lack direction ahead of Fed, BoE

(Alliance News) - Stock prices in London lacked direction at the open on Wednesday, as investors nervously look ahead to interest rate decisions from the US Federal Reserve and Bank of England.

Read more
31 Jan 2024 07:46

LONDON BRIEFING: Stocks called up; GSK revenue and profit up

(Alliance News) - Stocks in London are called to open higher, as markets share of nerves around the next set of interest rate decisions.

Read more
29 Jan 2024 08:51

GSK seeks expanded use of RSV vaccine in EU, wins approval for Omjjara

(Alliance News) - GSK PLC on Monday celebrated regulatory progress for two of its products in the EU.

Read more
29 Jan 2024 07:43

LONDON BRIEFING: Superdry looks at saving costs; Ferrexpo loses case

(Alliance News) - Stocks in London are expected to start the week on a cautious note, as investors nervously look ahead to two key interest rate decisions.

Read more
29 Jan 2024 07:07

GSK gets EU approval to sell blood cancer treatment Omijara

(Sharecast News) - Biopharma giant GSK has been given the green light by European regulators to sell Omjjara, its treatment for patients with a rare type of blood cancer.

Read more
26 Jan 2024 10:47

Citi hikes target price for GSK but stays 'neutral'

(Sharecast News) - Shares in biopharma giant GSK were rising on Friday, helped by forecast upgrades from Citi, which raised its target price on the stock from 1,535p to 1,700p.

Read more
24 Jan 2024 15:08

Private equity firm Yellow Wood close to deal to acquire ChapStick-sources

Jan 24 (Reuters) - Private equity firm Yellow Wood Partners is in advanced talks to acquire ChapStick, a lip balm brand, from Haleon Plc, the former consumer health division of drug developer GSK Plc, four people familiar with the matter said.

Read more
24 Jan 2024 14:34

UK earnings, trading statements calendar - next 7 days

Thursday 25 January 
Britvic PLCTrading Statement
Conduit Holdings LtdTrading Statement
CVS Group PLCTrading Statement
Dr Martens PLCTrading Statement
Fevertree Drinks PLCTrading Statement
Foxtons Group PLCFull Year Results
Fuller, Smith & Turner PLCTrading Statement
Halfords Group PLCTrading Statement
Idox PLCFull Year Results
IG Group Holdings PLCHalf Year Results
Intermediate Capital Group PLCTrading Statement
Mitie Group PLCTrading Statement
NCC Group PLCHalf Year Results
Newmark Security PLCHalf Year Results
Next 15 Group PLCTrading Statement
PPHE Hotel Group LtdTrading Statement
Secure Trust Bank PLCTrading Statement
St James's Place PLCTrading Statement
Time Finance PLCHalf Year Results
Titon Holdings PLCFull Year Results
Wizz Air Holdings PLCQ3 Results
Workspace Group PLCTrading Statement
Friday 26 January 
Paragon Banking Group PLCTrading Statement
Record PLCTrading Statement
Superdry PLCHalf Year Results
Taylor Maritime Investments LtdTrading Statement
WH Smith PLCTrading Statement
YouGov PLCTrading Statement
Monday 29 January 
Team Internet Group PLCTrading Statement
Tuesday 30 January 
Diaceutics PLCTrading Statement
Diageo PLCHalf Year Results
Kromek Group PLCHalf Year Results
Luceco PLCTrading Statement
Oxford Cannabinoid Technologies Holdings PLCHalf Year Results
Pets at Home Group PLCTrading Statement
Renewi PLCTrading Statement
Saga PLCTrading Statement
SSP Group PLCTrading Statement
SThree PLCFull Year Results
Synthomer PLCTrading Statement
Wednesday 31 January 
Aberforth Smaller Companies Trust PLCFull Year Results
abrdn Private Equity Opportunities Trust PLCFull Year Results
Ecora Resources PLCTrading Statement
GSK PLCFull Year Results
ITM Power PLCHalf Year Results
NWF Group PLCHalf Year Results
  
Comments and questions to newsroom@alliancenews.com
  
A full 21-day events calendar is provided each day with a subscription to Alliance News UK Professional.
  
Copyright 2024 Alliance News Ltd. All Rights Reserved.

Read more
22 Jan 2024 21:22

Fate of most remaining Zantac lawsuits weighed by Delaware judge

Jan 22 (Reuters) - GSK, Pfizer and other pharmaceutical companies are urging a judge in Delaware this week to find that evidence plaintiffs' lawyers want to use in about 72,000 lawsuits claiming that the discontinued heartburn drug Zantac caused cancer is not supported by science.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.